Therapy with an implantable cardioverter defibrillator (ICD) in patients with coronary artery disease and dilated cardiomyopathy: Benefits and disadvantages

Swiss Medical Weekly

Volumn 139, Issue 45-46, 2009, Pages 648-653

  Schaer, Beat ^a   Kühne, Michael ^a   Koller, Michael T ^a,b   Sticherling, Christian ^a   Osswald, Stefan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Competing risks; Coronary artery disease; Dilated cardiomyopathy; Implantable cardioverter defibrillator; Risk stratification

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ANXIETY; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; BYPASS SURGERY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; COST BENEFIT ANALYSIS; DEFIBRILLATOR; DEPRESSION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; EXERCISE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITAL COST; HUMAN; KIDNEY FAILURE; MORTALITY; PACEMAKER; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SHOCK; SHOCK WAVE; SUDDEN DEATH; SYNCOPE; TERMINAL CARE; TREATMENT INDICATION; ECONOMICS; EQUIPMENT;

CARDIOMYOPATHY, DILATED; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DEFIBRILLATORS, IMPLANTABLE; EQUIPMENT FAILURE ANALYSIS; HUMANS; RISK ASSESSMENT;

EID: 70449730895     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al.; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940
2. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341: 1882-1890
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883
4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al.; Sudden Cardiac Death in Heart Failure (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter - defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237
5. Sticherling C, Schaer B, Coenen M, Kühne M, Ammann P, Osswald S. Cardiac resynchronisation therapy in chronic heart failure. Swiss Med Wkly. 2006;136:611-617 (Pubitemid 44744678)
6. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1-62.
7. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML, et al., for the MADIT-II Investigators Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II J Am Coll Cardiol. 2006;47:1811-1817
8. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. on behalf of the investigators of the AVID, CASH and CIDS studies Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071-2078
9. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453-1458 (Pubitemid 34263277)
10. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al.; AMIOVIRT investigators. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-1712
11. Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP, et al. for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158
12. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150
13. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy. A meta-analysis of randomized controlled trial. JAMA. 2004;292:2874-2879
14. Cleland JCF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Cardiac Resynchronization-Heart Failure (CAREHF) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549
15. Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB, et al. Role of microvolt T-Wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-Wave Alternans Sudden Cardiac Death in Heart Failure Trial Substudy. Circulation. 2008;118:2022-2028
16. Daubert JP, Zareba W, Hall WJ, Schuger C, Corsello A, Leon AR, et al. for the MADIT II Study Investigators. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol. 2006;47:98-107.
17. Berkowitsch A, Zareba W, Neumann T, Erdogan A, McNitt S, Moss AJ, et al. Risk stratification using heart rate turbulence and ventricular arrhythmia in MADIT II: Usefulness and limitations of a 10-Minute Holter recording. Ann Noninvasive Electrocardiol. 2004; 9:270-279 (Pubitemid 39044080)
18. Buxton AE, Lee KL, Hafley GE, Wyse DG, Fisher JD, Lehmann MH, et al. fort he MUSTT investigators Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery diseases: an analysis of patients enrolled in the Multicenter Unsustained Tachycardia Trial. Circulation. 2002;106:2466-2472
19. Singh JP, Hall WJ, McNitt S, Wang H, Daubert J, Zareba W. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) J Am Coll Cardiol. 2005;46:1712-1720 (Pubitemid 41531628)
20. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala Ret al., DINAMIT Investigators Prophylactic use of an implantable cardioverter- defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-2488
21. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He Het al., for the MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288-296
22. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. for the MUSTT Investigators Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT Study. J Am Coll Cardiol. 2007;50:1150-1157
23. Koller MT, Schaer BA, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation. 2008; 117:1918-1926 (Pubitemid 351543467)
24. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al., for the MADIT II Investigators Inappropriate implantable cardioverter- defibrillator shocks in MADIT II: Frequency, mechanisms, predictors, and survival impact J Am Coll Cardiol. 2008;51:1357-1365
25. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115:2474-2480 (Pubitemid 46763220)
26. Eckstein J, Koller M, Zabel M, Kalusche D, Schaer B, Osswald S, et al. Necessity for surgical revision of chronically implanted defibrillator leads - causes and management. Circulation. 2008;117:2727-2733 (Pubitemid 351770453)
27. Biffi M, Ziacchi M, Bertini M, Sangiorgi D, Corsini D, Martignani C, et al. Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems. Europace. 2008;10:1288-1295
28. Ladwig KH, Wirsching C, Hammerstein A, Danner R, Baumert J, Schmitt C. Anxiety and management of anxiety in patients with implanted cardioverter-defibrillators. Dtsch Med Wochenschr. 2004;129:2311-2315 (Pubitemid 39452563)
29. Lemon J, Edelman S. Psychological adaptation to ICDs and the influence of anxiety sensitivity. Psychol Health Med. 2007;12:163-171 (Pubitemid 46255602)
30. Pedersen SS, van Domburg RT, Theuns DA, Jordaens L, Erdmann RA. Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks. Am Heart J. 2005;149:664-669 (Pubitemid 40501492)
31. Ector H, Vardas P. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: data from the registry of the European Heart Rhythm Association. Eur Heart J. 2007;S1:144-149